Status:

UNKNOWN

Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia

Lead Sponsor:

Beijing Chao Yang Hospital

Conditions:

Novel Coronavirus Pnuemonia

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

PHASE3

Brief Summary

This study is a multi-centered, three-armed, randomized, double-blinded, controlled study, namely, the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group (combined gro...

Eligibility Criteria

Inclusion

  • Male and female, 18-75 years old
  • Patients previously diagnosed with novel coronavirus pneumonia: the course of illness is no more than 14 days; if the course of the disease was more than 14 days, patient meets one of the following conditions can also be included in the group: (1) No apparent absorption or progression of chest radiograph was observed within 7 days; (2) respiratory symptoms (chest tightness, or cough, or breathing difficulties); (3) Test for viral nucleic acid positive within 3 days.
  • informed consent should be signed by the participate or an authorized agent
  • Agree to clinical samples collection
  • Female or male subjects of childbearing age agree to take effective contraceptive measures within 3 months of the last oral medication to ensure that female or male partners of childbearing age do not become pregnant

Exclusion

  • Severe vomiting or difficulty ingesting medication
  • Woman who are pregnant or during lactation
  • Patients received lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody specific antiviral drugs three days before enrollment
  • Cases of respiratory failure requiring mechanical ventilation
  • Shock
  • Combined with other organ failure and requires ICU care
  • Clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission

Key Trial Info

Start Date :

March 5 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 25 2020

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT04319900

Start Date

March 5 2020

End Date

June 25 2020

Last Update

March 24 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing Chaoyang hospital

Beijing, Beijing Municipality, China, 100020